The company’s products include GlycoPEG-EPO, which stimulates the production of red blood cells for the treatment of chemotherapy-induced anemia and anemia associated with chronic renal failure; and GlycoPEG-GCSF that stimulates the production of neutrophils for the treatment of neutropenia associated with myelosuppressive chemotherapy.
Neose Technologies has collaborations with BioGeneriX, Novo Nordisk A/S, and MacroGenics, Inc.
for the research and development of its GlycoAdvance and GlycoPEGylation technologies.
Neose Technologies was incorporated in 1989 and is headquartered in Horsham, Pennsylvania.
